We have sildenafil citrate tablets – 50mg and 100mg – for which we hold the MA in Germany and Spain. We would be interested to explore any out-licensing opportunity in the area of finished product supply or dossier for the same.

Athena have developed CTD dossiers on Oral Drug Delivery Products that we are looking to license out to partners who can receive products either in finished packs or bulk for local compression/encapsulation.

This product is identical in every respect to Seretide Diskus. MA was granted in one EU country in 2013 and is launched. It is still available for license in some EU countries, and for all countries outside of Europe except the USA.

This product is highly similar to Humira and is fully documented, with stability according to EU requirements; with regulatory analytics according to the EU requirements; and, proof of comparability in a phase I human study. Phase III pK/PD comparative clinical studies in humans were completed in 2013.

This once-daily generic product treats attention deficit disorder (ADHD) and is available for license outside the USA including Europe. It is manufactured in USA FDA inspected facility and launched in the USA.

This product (100 and 400mg vials) is highly similar to Avastin and is fully documented, with comparability and stability according to EU requirements; with regulatory analytics according to EU requirements; and, proof of comparability in a phase I pK/PD comparative clinical study in humans.

This product is highly similar to MabThera and is fully documented, with stability and comparability according to EU and USA requirements; and, proof of comparability with phase I and phase III pK/PD comparative clinical studies in humans.

Alkalon offers a range of finished product formulations and is seeking partnership opportunities worldwide.
2 and 4 mg available in several flavours.
Our Nicotine Polacrilex Chewing Gum portfolio is based on a high quality dossier and has received MA's in several EU countries.

Testimonials

Einar Geir Hreinsson, Vice-President Strategic Projects at Actavis, says:"We used this channel to reach potential customers and it turned out to be considerably more effective than we had expected. It is invaluable to be able to introduce a new project like Opening Pharma in this way, through a single portal with connections in all directions. This will be our first choice the next time we want to give a new project a good promotion."

Rich DiCicco, Chief Executive Officer of Harvest Moon Pharma, comments:"Harvest Moon Pharma has listed its complex generics and biosimilars on SourceGenerics for three years. We have received enquiries from 206 companies - including Pfizer, Sanofi, Teva, Stada, Ranbaxy and Sandoz - from 58 countries, and we are very pleased with the results. We intend to keep listing on SourceGenerics indefinitely."

Sanjiv Puri, Chief Executive Officer of Australia's Generic Partners, tells us:"Within a week of posting our business opportunities on SourceGenerics we had received over 10 quality enquiries from leading generics companies throughout the world."